Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus DICLOFENAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus DICLOFENAC.
BUTAZOLIDIN vs DICLOFENAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
None Documented
None Documented
Clinical Note
moderateDiclofenac + Gatifloxacin
"Diclofenac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiclofenac + Rosoxacin
"Diclofenac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiclofenac + Levofloxacin
"Diclofenac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiclofenac + Trovafloxacin
"Diclofenac may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Category C
Category D/X
NSAID
NSAID